Phase 2Completed
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)
- Sponsor
- OPKO Health, Inc. (Industry)
- Enrollment
- 171 enrolled
- Conditions
- COVID-19; Coronavirus; SARS-CoV2 Infection
- Interventions
- Rayaldee; Placebo
- Ages
- adults, older adults
- Registry
- NCT04551911
Full record on ClinicalTrials.gov
From the registry
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
Primary outcomes
- Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).
- Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.
History
Results first posted
Last registry update
Primary completion
Started
Registered